Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey.
about
Levomilnacipran for the treatment of major depressive disorder: a reviewLessons learned from placebo groups in antidepressant trialsChanges in body weight and psychotropic drugs: a systematic synthesis of the literatureSexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate.Sexual dysfunction associated with major depressive disorder and antidepressant treatment.Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats.Major depressive disorder: mechanism-based prescribing for personalized medicineComparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-AnalysisEfficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorderThe efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trialsMedication use patterns, health care resource utilization, and economic burden for patients with major depressive disorder in Beijing, People's Republic of China.Multi-modality: a new approach for the treatment of major depressive disorder.Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled StudyThe Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder.Learning to experience side effects after antidepressant intake - Results from a randomized, controlled, double-blind study.Weight gain associated with taking psychotropic medication: an integrative review.A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study.Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.Long-Term and Short-Term Antidepressant Use in General Practice: Data from a Large Cohort in the Netherlands.Self-Reported Adverse Drug Reactions, Medication Adherence, and Clinical Outcomes among Major Depressive Disorder Patients in Ethiopia: A Prospective Hospital Based Study.Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.The Clinician’s Role in Helping Patients to Take Antidepressants as PrescribedAdherence, Compliance, and Discontinuation in Depression
P2860
Q28083216-18D975C3-380A-4745-84CF-A7E7FC39F996Q28478927-D2F2DF87-00C3-4343-B2D2-B99D588E850EQ28728401-E4F6CACF-6E19-4A85-81B8-2ECDF255A583Q30384691-BB9FA0FA-304F-42DF-B439-31D5A95797F1Q30457019-7250D650-186D-4C30-A9CC-98D0D97B575AQ30458935-7339496A-0DC2-4985-B302-F0C9C61D3E41Q34024109-1CE5B471-1811-494F-AC05-C40E9BCE31ACQ34033547-7E24D6E4-3D9B-407C-A81D-CF8F9E7A1713Q34243328-7D291EC7-6681-46A1-8951-9C232BD8BDF3Q34675188-BFC2BDEE-C0B8-48EA-A54D-3AC3401A464AQ35284412-5262538C-AAB9-4022-8A27-CDA76945996AQ36020033-054ABA94-6CDE-4445-9C1E-3EF26E578CF5Q36216847-8144135C-066E-426F-BA55-7E19DB71576CQ36366194-B9004C34-C987-470F-963D-D7D9E337A0C5Q36653073-B3D85548-8EEE-454F-84F0-1F1948B90743Q36833956-7F712A5B-1461-4672-A48F-3ECD95CDC5F0Q36896252-12149C41-5913-473E-8601-E6B3A68901F3Q37285357-1F00071F-D866-4FE3-A256-C83172B86BB4Q37299972-0F213F72-10EA-4544-94A9-065348DF4C8EQ37578354-1E176085-722E-41F7-9C99-5C320DBC93D6Q37865068-510815AA-1988-42AF-9192-E2B2C260114AQ38249999-D7F4122B-3CB9-40EE-8C25-91400F280B59Q40062026-AEED48E6-5AA3-4BC5-AE2F-1F6ACC14CBA5Q47599068-2190D24E-D75C-4BC1-99D6-6231B2FB08C8Q47608840-B0889748-D914-4FDC-92F4-5465D8EED889Q47652074-7C427BE0-D143-46F8-953B-EDA6E87AA6CDQ47716057-D1C9E7FA-AAE3-4666-AD5A-1D7B0A544AF2Q58809475-4373C902-61A5-4315-8ECD-E765D125D31FQ58809488-58FF2B42-1BE9-4F9B-AC8A-571E06B35454
P2860
Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antidepressant-related adverse ...... : Results of a patient survey.
@en
Antidepressant-related adverse ...... : Results of a patient survey.
@nl
type
label
Antidepressant-related adverse ...... : Results of a patient survey.
@en
Antidepressant-related adverse ...... : Results of a patient survey.
@nl
prefLabel
Antidepressant-related adverse ...... : Results of a patient survey.
@en
Antidepressant-related adverse ...... : Results of a patient survey.
@nl
P2093
P2860
P1476
Antidepressant-related adverse ...... : Results of a patient survey.
@en
P2093
Adam Keller Ashton
Brenda D Jamerson
Christine Wagoner
Wendy L Weinstein
P2860
P304
P356
10.1016/J.CURTHERES.2005.04.006
P577
2005-03-01T00:00:00Z